Vaxart announces publication in npj Vaccines on norovirus candidate

Vaxart (VXRT) announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose, oral bivalent vaccine candidate in post-partum, breastfeeding women. Topline safety and immunogenicity results in lactating women were initially reported in April 2024; the newly published study additionally shows vaccine-induced functional norovirus-specific antibodies in breastmilk and serum from vaccinated women, and norovirus-specific IgA in the stool of their breastfed infants. A positive correlation between levels of breast milk IgA and infant stool IgA was observed.